Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01059760 · ClinicalTrials.gov registry record · NA

Expression of Longevity Genes in Response to Extended Fasting

A NA study of Cardiovascular Disease, sponsored by Intermountain Health Care.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT01059760: Completed NA study of Cardiovascular Disease, sponsored by Intermountain Health Care.

NCT01059760 is a NA study of Cardiovascular Disease that has completed, run by Intermountain Health Care. The registered enrollment target is 30 participants, below the 2,697-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01059760, a NA study of Cardiovascular Disease, has completed, sponsored by Intermountain Health Care.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the effect of fasting on physical changes associated with cardiovascular disease.

Conditions Studied

Interventions

  • BEHAVIORAL Fasting First
  • BEHAVIORAL Fed First

Study Locations (1)

Utah

  • Intermountain Medical Center - Murray

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2010-01
Est. Completion 2010-10
Phase NA
Intermountain Health Care

85 total trials

What the finished NCT01059760 record still lists

NCT01059760 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,697-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Fasting First is the first listed.

NCT01059760 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT01059760 about?

NCT01059760 is a clinical study titled "Expression of Longevity Genes in Response to Extended Fasting". The purpose of this study is to evaluate the effect of fasting on physical changes associated with cardiovascular disease.

What is the current status of trial NCT01059760?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2010-01. Estimated completion is 2010-10.

What conditions does trial NCT01059760 study?

This clinical trial studies the following conditions: Cardiovascular Disease.

What interventions are being tested in trial NCT01059760?

The interventions under investigation include: Fasting First (BEHAVIORAL), Fed First (BEHAVIORAL).

Who is sponsoring clinical trial NCT01059760?

This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01059760 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01059760's enrollment target sits among peer trials

30 125th of 137 higher than 11 of 137 other Cardiovascular Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01059760, the US trial registry maintained by the National Library of Medicine. NCT01059760 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.